16 words
PROACT: Can we prevent chemotherapy-related heart damage in patients with breast cancer and lymphoma?
Slide Presentation: PROACT: Can we prevent chemotherapy-related heart damage in patients with breast cancer and lymphoma?
Install
Latest in Metastatic Breast Cancer
660 words
Targeted drug shrinks tumors in 3 out of 4 patients with advanced breast cancer
Dr. Loren Rourke, a Texas-based breast surgical oncologist and author, emphasized that while no lifestyle choice can guarantee cancer prevention, healthy habits can help support the body and reduce certain risk factors. There may be a promising new treatment on…
228 words
PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance
Somatic alterations in the phosphoinositide 3-kinase (PI3K) pathway are frequent oncogenic drivers in cancer and are particularly relevant in estrogen receptor–positive breast cancer, where PI3K... PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance Somatic alterations in the phosphoinositide 3-kinase (PI3K) pathway…
595 words
Pembrolizumab Plus Chemo Improves PFS in PD-L1+ HR+/HER2– Breast Cancer
CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
328 words
HER2 positive breast cancer: Treatment de-escalation needs to be personalized
De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalised, according to Dr Carmen Criscitiello, European Institute of Oncology, Milan, Italy. Her comments come on the occasion of the presentation of updated research results at…
298 words
Late-Breaking Breast Cancer Data at ESMO 2026 Highlight ADCs and Ribociclib
THE COUNTDOWN IS ON Late-breaking ESMO 2026 data show PFS gains with 3 antibody-drug conjugates, a 6-year OS benefit with adjuvant ribociclib, and no OS gain with pembrolizumab. In each of the 3 ADC trials, led by investigators in China, median PFS more…
1,029 words
Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
27 Oct 2026 - 08:30 Enhertu ® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant…
1,020 words
Kelun Biotech publishes sac TMT breast cancer study in Annals of Oncology
Sichuan Kelun-Biotech Biopharmaceutical published overall survival analysis from its Phase III OptiTROP-Breast01 study in Annals of Oncology during the ESMO Congress in Madrid. Kelun Biotech publishes sac TMT breast cancer study in Annals of Oncology CHENGDU, China, Oct. 26, 2026 /PRNewswire/ -- Sichuan…
212 words
Optimizing Treatment Selection After Progression in HER2+ Metastatic Breast Cancer | Around the Practice | CancerNetwork
Panelists discuss how clinical data and treatment selection in later-line HER2+ metastatic breast cancer are informed by the latest therapeutic advancements, including targeted therapies like trastuzumab deruxtecan (T-DXd) and tucatinib, to optimize patient outcomes and manage progression. Panelists discuss how managing…
242 words
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
A phase 3, randomized, double-blind registration study in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar after switching studies. The study results were presented during a poster session at the 2017 Annual Meeting…
Metastatic Breast Cancer
Advanced and metastatic breast cancer: treatment advances, trials and living with stage 4 disease.
- 3 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.